



Inspired by **patients.**
Driven by **science.**



Prof. Dr. med.
Iris Loew-Friedrich

Executive Vice-President
Chief Medical Officer

Joined UCB in September 2006

Iris Loew-Friedrich is Chief Medical Officer for UCB, a member of the company's Executive Committee and Head of the Development Solutions. She provides strategic global leadership for worldwide clinical development, medical affairs, regulatory affairs, quality assurance, statistical innovation, real world evidence and patient safety/pharmacovigilance.

Her mission is to lead UCB's Development Solutions, ensuring high quality, innovative, cost-effective development of objectively differentiated patient solutions with proven superior and sustainable value for clearly defined patient populations.

Prior to UCB, Dr. Loew-Friedrich served as the head of Global Research and Development for Schwarz Pharma, which UCB moved to acquire in 2006. She was also on the Schwarz Pharma Executive Board.

Dr. Loew-Friedrich held several medical and R&D roles, including Vice-President and Head of Global Projects at BASF Pharma, Ludwigshafen, Germany; Vice-President, Head of Global Clinical Management, HMR/Aventis, and Therapeutic Area Head Rheumatology and Bone Diseases, Hoechst/HMR, Bridgewater, New Jersey.

Dr. Loew-Friedrich received her medical license from Johann Wolfgang Goethe University, Frankfurt, Germany, and her PhD, following a research assignment at the Max-Planck-Institute for Biophysics, in 1985. From 1985 to 1992, Dr. Loew-Friedrich was the staff physician at the Department for Internal Medicine at the Frankfurt University Medical School, with sub-specialties in immunology, nephrology, and transplantation medicine. She is board-certified in internal medicine and holds a professorship at Frankfurt University Medical School. Iris is active in industry associations and a member of the supervisory board of Evotec SE, Fresenius SE & Co. KGaA, TransCelerate, PhRMA Foundation and MAPS.

